Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abemaciclib + irinotecan + temozolomide + dinutuximab + granulocyte-macrophage colony-stimulating factor
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Abemaciclib + irinotecan + temozolomide + dinutuximab + granulocyte-macrophage colony-stimulating factor is an investigational multi-agent combination therapy being evaluated for the treatment of relapsed or refractory high-risk neuroblastoma. The regimen adds abemaciclib, a selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), to the established chemoimmunotherapy backbone of irinotecan and temozolomide (chemotherapy), dinutuximab (a chimeric monoclonal antibody targeting the GD2 disialoganglioside), and GM-CSF (a cytokine used to stimulate immune effector cells). This combination is currently being studied in the Phase 1b/2 JPCS trial (NCT04238819) to determine if the addition of cell cycle inhibition can improve clinical outcomes in pediatric and young adult patients who have failed prior therapies.
- Other names
- abemaciclib + irinotecan + temozolomide + dinutuximab + sargramostimI/T/DIN/GM-CSF + abemaciclibJPCS Part C regimen
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)GD2N7-G (DNA guanine-N7 adduct)CDK6 (Cyclin-dependent kinase 6)TOP1 (DNA Topoisomerase I)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on abemaciclib + irinotecan + temozolomide + dinutuximab + granulocyte-macrophage colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abemaciclib + irinotecan + temozolomide + dinutuximab + granulocyte-macrophage colony-stimulating factor.